Carnivore Diet for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Carnivore Diet for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Removing all plant foods shifts the body onto fat-derived fuel, eliminates every plant trigger, and loads the diet with saturated fat and animal protein. Weight, blood sugar control and digestive symptoms often improve, though the evidence is surveys of people who chose the diet. Blood cholesterol rises sharply, most in the leanest. No long-term comparison trials exist. (Full Review)

Protocol

Standard approach
Ruminant meat, salt and water
Eaten to appetite across one to three meals daily; no carbohydrate target, intake is inherently near zero
Protein and fat ratio
1.6–2.2 g protein/kg
Fat supplies the remaining energy, typically 70–80% of calories; excess protein relative to fat blunts ketosis
Adaptation period
2–6 weeks
Performance, sleep and bowel habit are unreliable guides before it completes
Time to effect
Weight and glycaemic change
1–2 weeks
First changes to appear
Gastrointestinal and skin
2–6 weeks
Typical emergence of symptom improvement
Lipid change
8–12 weeks
Lipid changes stabilise here, the earliest meaningful point to retest

Benefits

Contraindications
  • Familial hypercholesterolemia or established atherosclerotic cardiovascular disease (particularly untreated LDL cholesterol ≥190 mg/dL)
  • Chronic kidney disease stage 3b or worse (eGFR below 45 mL/min/1.73 m²)
  • Hepatic impairment of Child-Pugh Class B or C
  • Any urea-cycle or fatty-acid-oxidation disorder
  • Pregnancy, lactation, and childhood or adolescent growth
  • Active eating disorder or a history of restrictive eating disorder
  • Recurrent calcium oxalate or uric acid nephrolithiasis
  • Type 1 diabetes without specialist supervision
  • SGLT2 inhibitors that cannot be discontinued (empagliflozin, dapagliflozin, canagliflozin)
    •
Key Interactions
  • Insulin and sulfonylureas (glipizide, glimepiride, gliclazide): severe hypoglycaemia
  • Warfarin: altered anticoagulation
  • Antihypertensives and diuretics (furosemide, hydrochlorothiazide, lisinopril): symptomatic hypotension
  • Lithium: altered lithium concentrations
  • Statins and other lipid-lowering therapy (atorvastatin, rosuvastatin, ezetimibe): monitor
  • Over-the-counter medications: antacids and proton-pump inhibitors (omeprazole, pantoprazole), non-steroidal anti-inflammatory drugs (ibuprofen, naproxen), laxatives
  • Supplement interactions: vitamin C above 1,000 mg daily
  • Supplements with additive effects: exogenous ketone salts and esters, berberine, chromium, fish oil
  • Other interventions: GLP-1 receptor agonists (semaglutide, tirzepatide), prior bariatric surgery
    •

Risk & Side Effects

  • High: Marked elevation of LDL cholesterol and apolipoprotein B
    •
  • Medium: Increased colorectal cancer risk at high red and processed meat intake; higher incidence of type 2 diabetes at high meat intake
    •
  • Low: Gastrointestinal disturbance; micronutrient inadequacy; ketogenic adaptation symptoms and electrolyte depletion; raised uric acid and gout flares; kidney stone formation; sustained growth-pathway activation from high animal protein; reduced bone mineral density
    •
  • Speculative: Loss of fibre-derived short-chain fatty acids and microbiome narrowing; elevated trimethylamine N-oxide
    •

Monitoring

Marker Target Why
Apolipoprotein B <80 mg/dL; <60 mg/dL if plaque is present Counts artery-damaging particles directly
LDL cholesterol <100 mg/dL Tracks the diet’s largest and most consistent effect
Lipoprotein(a) <30 mg/dL (<75 nmol/L) Inherited particle that multiplies the risk of any given particle count
Triglyceride-to-HDL ratio <1.5 in mg/dL units Marks insulin resistance and predicts who will hyper-respond
HbA1c 4.8–5.4% Three-month average glycaemic control
Fasting insulin 2–5 µIU/mL Detects metabolic improvement long before glucose moves
Fasting glucose 75–90 mg/dL Baseline glucose control
hs-CRP <0.5 mg/L General systemic inflammation
Uric acid 3.5–6.0 mg/dL Tracks gout and stone risk during adaptation
Creatinine with cystatin C and eGFR eGFR >90 mL/min/1.73 m² Kidney function under a sustained high protein load
Sodium, potassium, magnesium Sodium 138–142 mmol/L; potassium 4.0–4.5 mmol/L; red-cell magnesium 5.0–6.5 mg/dL Explains most early adverse symptoms
Plasma vitamin C 0.8–1.5 mg/dL The nutrient carnivore menus most reliably fail to supply
25-hydroxyvitamin D with parathyroid hormone Vitamin D 40–60 ng/mL; parathyroid hormone 15–35 pg/mL Bone risk from low calcium intake and mild acid load
Thyroid panel (TSH, free T3) TSH 0.5–2.0 mIU/L; free T3 3.0–4.0 pg/mL Detects the energy-conservation shift of sustained carbohydrate restriction
Ferritin with transferrin saturation Ferritin 50–150 ng/mL; saturation 25–35% High heme iron intake can push iron into excess
Coronary artery calcium score 0 Agatston units Direct evidence of whether plaque is actually present
DEXA bone mineral density T-score above −1.0 Bone consequence of low calcium and mild acidosis

Cadence: Baseline before the first plant-free meal; electrolytes and kidney function at 4 weeks; full lipid and metabolic panel at 12 weeks, then every 6 months; coronary imaging repeats at 2–3 years where the lipid response is large

Qualitative Assessment

  • Energy stability through the day, particularly the absence of mid-afternoon fatigue
  • Sleep duration and the number of night-time awakenings
  • Digestive symptoms: bloating, pain, stool form and frequency
  • Joint pain and morning stiffness, scored consistently on the same scale
  • Skin appearance, including eczema, psoriasis and acne
  • Cognitive clarity and the ability to sustain concentration
  • Exercise performance, separated into strength, sprint and endurance capacity
  • Appetite and the absence or presence of food preoccupation
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.